Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
- 9 May 2009
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 93 (1) , 61-77
Abstract
Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2. We review the challenges of NF2 clinical trials and suggest possible response criteria for use in initial phase II studies. We suggest two main response criteria in such trials. Objective radiographic response is defined as a durable 20% or greater reduction in VS volume based on post-contrast T1-weighted MRI images collected with 3 mm or finer cuts through the internal auditory canal. Hearing response is defined as a statistically significant improvement in word recognition scores using 50-word recorded lists in audiology. A possible composite endpoint incorporating both radiographic response and hearing response is outlined. We emphasize pitfalls in response assessment and suggest guidelines to minimize misinterpretations of response. We also identify research goals in NF2 to facilitate future trial conduct, such as identifying the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors (such as age, baseline tumor volume, and measures of disease severity). These data would facilitate future use of endpoints based on stability of tumor size and hearing, which might be more appropriate for testing certain drugs. We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents.Keywords
This publication has 155 references indexed in Scilit:
- ErbB and NrgOtology & Neurotology, 2008
- Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomasBMC Cancer, 2007
- Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform NeurofibromasPediatric Neurology, 2007
- The randomized discontinuation trial: a phase II design to assess growth-inhibitory agentsMolecular Cancer Therapeutics, 2007
- Two- and three dimensional measures of vestibular schwannomas and posterior fossa – implications for the treatmentActa Neurochirurgica, 2007
- Setting the Bar in Phase II Trials: The Use of Historical Data for Determining “Go/No Go” Decision for Definitive Phase III TestingClinical Cancer Research, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Evaluation of Randomized Discontinuation DesignJournal of Clinical Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Bilateral acoustic neurofibromatosis camouflaged by corticosteroid treatment of sudden sensorineural hearing lossIrish Journal of Medical Science (1971 -), 1996